Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Transcenta and Agilent Collaborate on Companion Diagnostic for Claudin18.2 mAb

publication date: Apr 12, 2024

Suzhou Transcenta partnered with California’s Agilent Technologies to develop a companion diagnostic for Osemitamab, a Claudin18.2 mAb. Transcenta has developed a mouse anti-CLDN18.2 monoclonal antibody, clone 14G11, that specifically binds to CLDN18.2 but not CLDN18.1. The antibody, generated against a linear epitope located on the extracellular domain of loop 1, has a binding site that overlaps the binding site of Osemitamab. Agilent is developing an immunohistochemistry assay that detects CLDN18.2 protein. Transcenta will use the assay to select patients for the Phase III trial of Osemitamab in gastric and gastroesophageal junction adenocarcinoma. More details....

Stock Symbol: (HK: 06628)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here